40 results
Page 2 of 2
8-K
EX-99.1
mld9y21 uzw
17 Feb 21
Blueprint Medicines Reports Fourth Quarter and Full Year 2020 Financial Results
8:00am
8-K
EX-99.2
cjr41qkgi
11 Jan 21
Entry into a Material Definitive Agreement
8:20am
424B5
18tjq6jkon0312
31 Jul 20
Prospectus supplement for primary offering
4:00pm
8-K
EX-99.1
lh7zkmf6luyxt41nza18
30 Jul 20
Blueprint Medicines Reports Second Quarter 2020 Financial Results
7:38am
8-K
EX-99.1
i6affavqy4vny
14 Jul 20
Blueprint Medicines Announces Global Collaboration with Roche to Develop and Commercialize Pralsetinib for Patients with RET-Altered Cancers
6:27am
424B5
a4nh4xtyrac
23 Jan 20
Prospectus supplement for primary offering
4:24pm
424B5
phs790wqcfmq5
21 Jan 20
Prospectus supplement for primary offering
4:44pm
8-K
EX-99.1
q5eniswm6pno
13 Jan 20
Regulation FD Disclosure
8:30am
8-K
EX-99.1
vyhfa9
5 Nov 19
Results of Operations and Financial Condition
7:16am
8-K
EX-99.1
3rvv4mkay xu9
16 Oct 19
Entry into a Material Definitive Agreement
6:51am
8-K
EX-99.1
tcgb1bbjr
4 Jun 19
Regulation FD Disclosure
7:30am
DRS
bvfaq6wn 28ekwusk0
19 Feb 15
Draft registration statement
12:00am